Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQB3570
- Development stage
- Preclinical
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TQB3570 is an investigational pembrolizumab biosimilar being developed by Chia Tai Tianqing, a core subsidiary of Sino Biopharmaceutical. It is a monoclonal antibody designed to target the programmed cell death protein 1 (PD-1) immune checkpoint, mimicking the mechanism of action of the reference product, Merck's Keytruda (pembrolizumab). In September 2026, Chia Tai Tianqing entered into a strategic partnership with STADA, granting STADA exclusive commercialization rights for TQB3570 in the European Union, Switzerland, the United Kingdom, and the Commonwealth of Independent States (CIS), with options for the United States and Gulf Cooperation Council (GCC) markets. TQB3570 is currently in early-stage development and has not yet entered clinical trials.
- Other names
- pembrolizumab biosimilarpembrolizumab biosimilar TQB3570
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on TQB3570.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQB3570.